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ABSTRACT
The automated MagNA Pure DNA extraction
method for Chlamydia trachomatis was compared
with the manual Cobas Amplicor protocol using
100 lL of input sample volume from 964 speci-
mens. Agreement between protocols was 96.1%.
The automated extraction method had a sensitiv-
ity of 99% and a specificity of 100%. Amplifica-
tion inhibition observed after manual preparation
of samples (3.8%) was not apparent following
automated extraction. Using 200 lL of sample in
the automated extraction process lowered the
detection limit without raising the inhibition rate.
Furthermore, the automated extraction method
halved the hands-on time required for the proce-
dure.
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Lower genital tract chlamydiosis is the most
frequent sexually transmitted bacterial infection
among young people in the world [1]. Often
asymptomatic, it can lead to inflammatory pelvic
disease and severe reproductive disorders if
untreated. The Cobas Amplicor system (Roche
Diagnostics, Meylan, France) allows automation
of the amplification and detection of Chlamydia
trachomatis DNA, but the DNA preparation pro-
cess remains manual. Using the MagNA Pure LC
robot and DNA isolation kit I (Roche), a DNA
preparation protocol (Table 1) was designed and
compared to the Cobas Amplicor CT ⁄NG manual
extraction procedure.
During a 19-month period, 964 consecutive
specimens (Table 2), 608 (63%) from women,
were tested retrospectively using the two DNA
preparation methods in parallel. Urogenital
swabs were placed in 2-sucrose-phosphate (2SP)
medium, while semen and first void urine (FVU)
samples or peritoneal fluids (PF) were collected
into sterile vials. All specimens were delivered to
the laboratory within 4 h, where a 100-lL aliquot
of PF was added to 2SP medium. All samples
were stored at 4C unless analysis was delayed
for > 2 days, when samples were stored at ) 80C.
Aliquots of semen (100 lL), FVU (500 lL) or
2SP medium inoculated with a urogenital swab or
PF (100 lL) were processed as shown in Table 1.
In the second phase, manual extraction of 100 lL
of inoculated 2SP and semen samples was com-
pared with MagNa Pure extraction using aliquots
of 100 lL and 200 lL. When discrepancies were
observed between the PCR results obtained after
manual extraction and MagNA Pure extraction,
aliquots of the original sample stored at –80C
were re-extracted by both methods and re-ampli-
fied once.
Using 100 lL aliquots, the results with the two
DNA preparation methods were concordant for
926 (96.1%) specimens (Table 2), of which 830
were uniformly negative. Thus the specificity of
MagNA Pure extraction was 100%, taking man-
ual extraction as the reference standard. No false-
positives were detected following MagNA Pure
extraction, in contrast with a previous study [2]
that reported a variable proportion of false-pos-
itive results, depending on the type of sample
analysed (0.1% of genital swabs; 1% of urine
specimens). Among the 97 positive samples
following manual extraction, 96 were positive
following automated extraction. Thus, taking
manual extraction as the reference standard, the
sensitivity of MagNA Pure extraction was 99%.
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One cervicovaginal swab was negative following
automated extraction, perhaps because of the low
number of DNA copies in the 100-lL aliquot,
since this sample was positive after repeating the
MagNA Pure extraction with a 200-lL aliquot of
the same specimen.
To assess the detection limit of the two extrac-
tion methods, serial dilutions of pooled positive
samples were extracted by the manual protocol
(100-lL aliquots) and by the MagNA Pure proto-
col (100-lL and 200-lL aliquots). The highest
dilution that was reproducibly positive was 1 : 8
with 200-lL samples, whereas a 1 : 4 dilution was
the detection limit with 100-lL samples.
Amplification of 37 (3.8%) samples was inhib-
ited following manual DNA preparation, whereas
no inhibition was observed following MagNA
Pure extraction, as has been described previously
for DNA purification from other bacteria [3].
Among these 37 samples, one cervicovaginal
swab proved to be positive, while the remaining
36 samples were PCR-negative. Semen and FVU
were inhibited more frequently (10.0% and
11.5%, respectively). Variable inhibition rates
(2.7% to 15%) have been reported previously
for urine samples [4–9], especially female urine
[5,10,11]. In the present study, among 52 FVU (38
male) samples, five of the six inhibited samples
were from females, giving an inhibition rate of
37.5% for female samples, but only 2.6% for male
samples. Mahony et al. [6] observed that PCRT
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Table 2. PCR results for detection of Chlamydia trachomatis
DNA in 964 urogenital samples according to the specimen
type and sample preparation method
Specimen
No. of
samples
No. of positive, negative and inhibited
samplesa according to the extraction
method
Manual
MagNa Pure
Positive Negative Inhibited
Cervicovaginal swab 558 Positive 41 1 0
Negative 0 508 0
Inhibited 1 7 0
Peritoneal fluid 36 Positive 5 0 0
Negative 0 31 0
Inhibited 0 0 0
Urethral swab 94 Positive 12 0 0
Negative 0 82 0
Inhibited 0 0 0
Semen 224 Positive 0 0 0
Negative 0 201 0
Inhibited 0 23 0
First-void urine 52 Positive 38 0 0
Negative 0 8 0
Inhibited 0 6 0
a100-lL sample volumes processed.
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inhibition with FVU samples was associated
most frequently with b human chorionic gonado-
trophin and crystals.
To investigate the effect on the inhibition rate
of using a double volume (200 lL) of sample for
automated DNA extraction, a complementary set
of 90 consecutive specimens (30 cervicovaginal
samples, 30 urethral samples, 30 semen samples)
was amplified following manual extraction
(100 lL) and automated extraction (200 lL). Six
samples were positive and 77 samples were
negative with both extraction methods. No
sample contained inhibitors following MagNA
Pure extraction of the 200-lL sample. Seven
samples (three cervicovaginal samples and four
semen samples) that contained inhibitors follow-
ing manual extraction were found to be PCR-
negative following MagNA Pure extraction.
Therefore, because of the lower detection limit
and lack of amplification inhibitors, the MagNA
Pure method using 200-lL sample volumes was
considered to be the most effective DNA extrac-
tion method.
Preparation of 24 urogenital swabs for
C. trachomatis DNA detection took 45 min of
hands-on time when using the MagNA Pure
extraction protocol, compared with 1 h 30 min
with the manual Cobas extraction protocol. The
amount of time saved was even greater with other
types of sample, such as FVU or semen, since
automated extraction required only one manual
pre-treatment step before processing, and there-
fore allowed easy preparation of all types of
sample in the same run. Reagents and consum-
ables costs were three-fold greater for the MagNA
Pure extraction method (6.85 Euros ⁄ assay) than
for manual extraction (2.05 Euros ⁄ assay), but
technician costs were estimated to be two-fold
less for MagNA Pure extraction (0.90 Euros ⁄
assay) than for manual extraction (1.81 Euros ⁄
assay). Absence of inhibitors following automated
extraction avoided the cost of repeated assays, as
well as delays in obtaining the corresponding
results. With a 3.8% inhibition rate, an additional
indirect cost of 0.45 Euros ⁄ assay must be taken
into account when using the manual extraction
method. Nevertheless, the overall cost of
C. trachomatis DNA detection using automated
extraction was 20% more expensive than the
manual extraction method, including reagents for
extraction and amplification, consumables and
technician time. This should also be balanced
against the fact that the MagNA Pure robot is
capable of performing DNA extraction and PCR
assembly without human manipulation, which
should therefore help to prevent PCR contamin-
ation during routine work.
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ABSTRACT
Enterobacter cloacae (n = 110) isolates from a
district hospital in Taiwan were screened for
extended-spectrum b-lactamases (ESBLs). In to-
tal, 17 ESBL-producers were identified, based on
the combination-disk synergy test using cefotax-
ime and ceftazidime ± clavulanic acid. Investiga-
tion of ESBL genes in 33 ceftazidime-resistant
isolates revealed the SHV-12 gene in the same 17
ESBL-producers. In addition, one isolate also
carried the CTX-M-3 gene, and two isolates also
carried the CTX-M-9 gene. No major epidemic
clone of ESBL-producers was identified by
pulsed-field gel electrophoresis. Routine screen-
ing for the ESBL phenotype, focusing on ceftaz-
idime-resistant E. cloacae, should be undertaken
in this area.
Keywords CTX-M-3, CTX-M-9, Enterobacter cloacae,
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Enterobacter cloacae is a major nosocomial patho-
gen, with susceptibility rates to cefotaxime or
ceftazidime in Taiwan of 35–60% [1,2]. In con-
trast, the fourth-generation cephalosporin cefepi-
me has remained highly active against E. cloacae
[2]. These resistance profiles suggest that AmpC
derepression or hyper-production is conferring
resistance to the third-generation cephalosporins
[3]. However, production of extended-spectrum
b-lactamases (ESBLs) by E. cloacae isolates in
Taiwan [4,5] and worldwide [6–8] has been
reported, raising the possibility of therapeutic
failure with isolates apparently susceptible to
cefepime [9]. Recently, SHV-12 carriage has been
identified among E. cloacae isolates from two large
(>1200 beds) hospitals in northern Taiwan [4,5].
Therefore, the aim of the present study was to
identify and characterise any ESBLs present
among the E. cloacae isolates from a district
hospital (c.600 beds) in a rural area of central
Taiwan.
During 2001, 110 non-repetitive isolates of E.
cloacae were collected from specimens of wound
pus (35%), urine (25%), sputum (20%), blood
(10%), catheter tips (6%) and drained pus (4%).
MICs for all isolates were determined by the agar
microdilution method, with the ESBL phenotype
being indicated by a reduction of ‡ 3 log2 dilu-
tions in the MICs of either ceftazidime (CAZ) or
cefotaxime (CTX) in the presence of clavulanic
acid 4 mg ⁄L [10]. Combination-disk synergy tests
using CTX (30 lg) or CAZ (30 lg) ± clavulanic
acid (CLA; 10 lg) were compared as a test for the
presence of ESBLs, which was confirmed by a
‡ 5-mm increase in zone diameter size for
CTX + CLA or CAZ + CLA vs. the zone diameter
size when CTX or CAZ was tested alone [11]. The
double-disk synergy test, using cefepime and
amoxycillin-clavulanic acid disks (placed 20 mm
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